Meeting
2016 Gastrointestinal Cancers Symposium
Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC).
Authors
Marc Peeters
Antwerp University Hospital, Edegem, Belgium
Marc Peeters , Tae Won Kim , Jin Li , Stefano Cascinu , Paul Ruff , Attili Venkatasatya Suresh , Anne Thomas , Sergei Tjulandin , Xuesong Guan , Tien Hoang , Yong Jiang Hei , Timothy Jay Price
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Prevention, Diagnosis, and Screening
Clinical Trial Registration Number
NCT01001377
Citation
J Clin Oncol 34, 2016 (suppl 4S; abstr 507)
DOI
10.1200/jco.2016.34.4_suppl.507
Abstract #
507
Poster Bd #
A20
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT.
First Author: Marc Peeters
Poster
2015 Gastrointestinal Cancers Symposium
Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.
First Author: Timothy Jay Price
Poster
2018 Gastrointestinal Cancers Symposium
Panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer who received prior bevacizumab therapy: A combined analysis of individual patient data from ASPECCT and WJOG6510G.
First Author: Hiroya Taniguchi
Poster
2016 Gastrointestinal Cancers Symposium
An open label, randomized phase 3 trial evaluating the treatment (tx) effects of panitumumab (pmab) + best supportive care (BSC) versus BSC in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC) and in WT RAS mCRC.
First Author: Tae Won Kim